The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation
Status:
Recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of multiple dose levels of PC14586 in
participants with advanced solid tumors containing a p53 Y220C mutation.